Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Anti-LRP2 Nephropathy With Abundant IgG4-Positive Plasma Cells: A Case Report.

Dinesh KP, Raniele D, Michels K, Avasare RS, Larsen CP, Kayton R, Khalighi MA, Andeen NK.

Am J Kidney Dis. 2019 Jul;74(1):132-137. doi: 10.1053/j.ajkd.2018.12.039. Epub 2019 Mar 12.

PMID:
30876746
2.

Kidney Transplantation in C3 Glomerulopathy: A Case Series.

Regunathan-Shenk R, Avasare RS, Ahn W, Canetta PA, Cohen DJ, Appel GB, Bomback AS.

Am J Kidney Dis. 2019 Mar;73(3):316-323. doi: 10.1053/j.ajkd.2018.09.002. Epub 2018 Nov 7.

PMID:
30413277
3.

Collapsing glomerulopathy in older adults.

Kukull B, Avasare RS, Smith KD, Houghton DC, Troxell ML, Andeen NK.

Mod Pathol. 2019 Apr;32(4):532-538. doi: 10.1038/s41379-018-0154-z. Epub 2018 Oct 16.

PMID:
30327500
4.

Nephrotoxicity of Select Rheumatologic Drugs.

Woodell T, Avasare RS.

Rheum Dis Clin North Am. 2018 Nov;44(4):605-617. doi: 10.1016/j.rdc.2018.06.005. Epub 2018 Sep 7. Review.

PMID:
30274626
5.

Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series.

Avasare RS, Canetta PA, Bomback AS, Marasa M, Caliskan Y, Ozluk Y, Li Y, Gharavi AG, Appel GB.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):406-413. doi: 10.2215/CJN.09080817. Epub 2018 Jan 11.

6.

C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.

Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, Radhakrishnan J, Marasa M, Rosenstiel PE, Herlitz LC, Markowitz GS, D'Agati VD, Appel GB.

Kidney Int. 2018 Apr;93(4):977-985. doi: 10.1016/j.kint.2017.10.022. Epub 2018 Jan 6.

PMID:
29310824
7.

Plasma metabolite profiles, cellular cholesterol efflux, and non-traditional cardiovascular risk in patients with CKD.

Ganda A, Yvan-Charvet L, Zhang Y, Lai EJ, Regunathan-Shenk R, Hussain FN, Avasare R, Chakraborty B, Febus AJ, Vernocchi L, Lantigua R, Wang Y, Shi X, Hsieh J, Murphy AJ, Wang N, Bijl N, Gordon KM, de Miguel MH, Singer JR, Hogan J, Cremers S, Magnusson M, Melander O, Gerszten RE, Tall AR.

J Mol Cell Cardiol. 2017 Nov;112:114-122. doi: 10.1016/j.yjmcc.2017.05.001. Epub 2017 May 4.

8.

Predicting Post-Transplant Recurrence of IgA Nephropathy: The Importance of Crescents.

Avasare RS, Rosenstiel PE, Zaky ZS, Tsapepas DS, Appel GB, Markowitz GS, Bomback AS, Canetta PA.

Am J Nephrol. 2017;45(2):99-106. doi: 10.1159/000453081. Epub 2017 Jan 6.

9.

Filgrastim-Induced Crescentic Transformation of Recurrent IgG2λ GN.

Batal I, Markowitz GS, Wong W, Avasare R, Mapara MY, Appel GB, D'Agati VD.

J Am Soc Nephrol. 2016 Jul;27(7):1911-5. doi: 10.1681/ASN.2016010061. Epub 2016 May 4.

10.

Proteinuria as a surrogate marker for renal outcome: are we there yet?

Avasare RS, Radhakrishnan J.

Kidney Int. 2015 Dec;88(6):1228-1230. doi: 10.1038/ki.2015.301.

PMID:
26649661
11.

Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis.

Hogan J, Avasare R, Radhakrishnan J.

Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1657-67. doi: 10.2215/CJN.01600214. Epub 2014 May 15. Review.

12.

Aldosterone blockade as an alternative renin-angiotensin-aldosterone system blocking agent in cases of treatment associated anemia.

Avasare RS, Appel GB, Bomback AS.

Clin Nephrol. 2014 May;81(5):350-4. doi: 10.5414/CN107677.

PMID:
23211336
13.

Fabrication and biocompatibility of polypyrrole implants suitable for neural prosthetics.

George PM, Lyckman AW, LaVan DA, Hegde A, Leung Y, Avasare R, Testa C, Alexander PM, Langer R, Sur M.

Biomaterials. 2005 Jun;26(17):3511-9.

PMID:
15621241

Supplemental Content

Loading ...
Support Center